Cimetidine enhances antigen-specific IgE and Th2 cytokine production. 2011

Ken Arae, and Keisuke Oboki, and Tatsukuni Ohno, and Masako Hirata, and Susumu Nakae, and Haruhiko Taguchi, and Hirohisa Saito, and Toshiharu Nakajima
Department of Immunology, Faculty of Health Sciences, Kyorin University, Tokyo, Japan.

BACKGROUND Treatment with anti-ulcer drugs has been shown to enhance IgE production against food antigens. However, little is known about the immunological effects of cimetidine, a histamine receptor type 2 (H2R) antagonist that is widely used as an anti-ulcer drug, in allergy. Therefore, the present study investigated the role of cimetidine in Th2 immune responses in mice. METHODS BALB/c mice were immunized intraperitoneally with ovalbumin (OVA) with and without cimetidine. The levels of cytokines in supernatants of spleen cells cultured in the presence of OVA for 4 days and the levels of total and OVA-specific IgG(1), IgG(2a) and/or IgE in sera from these mice were determined by ELISA. RESULTS Administration of cimetidine to OVA-sensitized BALB/c mice promoted Th2 cytokine secretion by OVA-stimulated spleen cells in vitro and increased serum levels of OVA-specific IgE, IgG(1) and IgG(2a). CONCLUSIONS These results indicate that cimetidine can enhance Th2 responses, suggesting that cimetidine may contribute to IgE production in allergies.

UI MeSH Term Description Entries
D006967 Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen. Allergy,Allergic Reaction,Allergic Reactions,Allergies,Hypersensitivities,Reaction, Allergic,Reactions, Allergic
D007073 Immunoglobulin E An immunoglobulin associated with MAST CELLS. Overexpression has been associated with allergic hypersensitivity (HYPERSENSITIVITY, IMMEDIATE). IgE
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D012137 Respiratory System The tubular and cavernous organs and structures, by means of which pulmonary ventilation and gas exchange between ambient air and the blood are brought about. Respiratory Tract,Respiratory Systems,Respiratory Tracts,System, Respiratory,Tract, Respiratory
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002927 Cimetidine A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. Altramet,Biomet,Biomet400,Cimetidine HCl,Cimetidine Hydrochloride,Eureceptor,Histodil,N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine,SK&F-92334,SKF-92334,Tagamet,HCl, Cimetidine,Hydrochloride, Cimetidine,SK&F 92334,SK&F92334,SKF 92334,SKF92334
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic

Related Publications

Ken Arae, and Keisuke Oboki, and Tatsukuni Ohno, and Masako Hirata, and Susumu Nakae, and Haruhiko Taguchi, and Hirohisa Saito, and Toshiharu Nakajima
January 1997, Toxicology,
Ken Arae, and Keisuke Oboki, and Tatsukuni Ohno, and Masako Hirata, and Susumu Nakae, and Haruhiko Taguchi, and Hirohisa Saito, and Toshiharu Nakajima
October 2006, Journal of nutritional science and vitaminology,
Ken Arae, and Keisuke Oboki, and Tatsukuni Ohno, and Masako Hirata, and Susumu Nakae, and Haruhiko Taguchi, and Hirohisa Saito, and Toshiharu Nakajima
May 2016, Journal of immunology (Baltimore, Md. : 1950),
Ken Arae, and Keisuke Oboki, and Tatsukuni Ohno, and Masako Hirata, and Susumu Nakae, and Haruhiko Taguchi, and Hirohisa Saito, and Toshiharu Nakajima
June 1996, European journal of immunology,
Ken Arae, and Keisuke Oboki, and Tatsukuni Ohno, and Masako Hirata, and Susumu Nakae, and Haruhiko Taguchi, and Hirohisa Saito, and Toshiharu Nakajima
January 1996, Immunological investigations,
Ken Arae, and Keisuke Oboki, and Tatsukuni Ohno, and Masako Hirata, and Susumu Nakae, and Haruhiko Taguchi, and Hirohisa Saito, and Toshiharu Nakajima
January 1996, Advances in experimental medicine and biology,
Ken Arae, and Keisuke Oboki, and Tatsukuni Ohno, and Masako Hirata, and Susumu Nakae, and Haruhiko Taguchi, and Hirohisa Saito, and Toshiharu Nakajima
January 2010, Journal of nutritional science and vitaminology,
Ken Arae, and Keisuke Oboki, and Tatsukuni Ohno, and Masako Hirata, and Susumu Nakae, and Haruhiko Taguchi, and Hirohisa Saito, and Toshiharu Nakajima
December 2007, European journal of clinical investigation,
Ken Arae, and Keisuke Oboki, and Tatsukuni Ohno, and Masako Hirata, and Susumu Nakae, and Haruhiko Taguchi, and Hirohisa Saito, and Toshiharu Nakajima
May 2000, Toxicology and applied pharmacology,
Ken Arae, and Keisuke Oboki, and Tatsukuni Ohno, and Masako Hirata, and Susumu Nakae, and Haruhiko Taguchi, and Hirohisa Saito, and Toshiharu Nakajima
October 2011, Journal of ethnopharmacology,
Copied contents to your clipboard!